Johnson & Johnson announces positive results in psoriasis

Published: 2025-09-17 10:03:46 ET JNJ

Published on 09/17/2025 at 10:03 am EDT

Johnson & Johnson announces new Phase 3 data on icotrokinra, an oral peptide targeting the IL-23 receptor, presented at the EADV 2025 congress.The ICONIC-ADVANCE 1 and 2 studies demonstrate its superiority over deucravacitinib in adult patients with moderate-to-severe plaque psoriasis, with significantly higher rates of complete skin clearance at week 16 and reinforced at week 24. Adverse effects remained comparable to placebo and lower than deucravacitinib.The ICONIC-LEAD study, including adults and adolescents, confirms sustained efficacy up to 52 weeks. In adults, 84% of patients maintained a PASI 90 response compared to 21% on placebo. Among adolescents, 86% achieved PASI 90 after one year of treatment.The study's principal investigator highlights the potential of this innovative oral treatment to offer an attractive new option. Johnson & Johnson has also launched ICONIC-ASCEND, the first trial comparing an oral treatment with an injectable biologic (ustekinumab) in psoriasis.